21 Years of biologically effective dose

British Journal of Radiology

Volumn 83, Issue 991, 2010, Pages 554-568

  Fowler, Jack F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON; RADIOISOTOPE;

BIOLOGICAL MODEL; BIOLOGICALLY EFFECTIVE DOSE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL KILLING; CELL SURVIVAL; CYBERKNIFE; DOSIMETRY; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; LINEAR ENERGY TRANSFER; MATHEMATICAL ANALYSIS; MEDICAL LITERATURE; MULTIMODALITY CANCER THERAPY; PARAMETER; PARTICLE RADIATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TIME; TOMOTHERAPY;

ALGORITHMS; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; LINEAR ENERGY TRANSFER; MODELS, BIOLOGICAL; MUCOUS MEMBRANE; RADIATION DOSAGE; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; TERMINOLOGY AS TOPIC;

EID: 77954465652     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/31372149     Document Type: Review

References (36)

1. Dale RG, Jones B. The assessment of RBE effects using the concept of biologically effective dose. Int J Radiat Oncol Biol Phys 1999;43:639-45. (Pubitemid 29107189)
2. Dale RG, Carabe-Ferandez A. the radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47-51.
3. Carabe-Fernandez A, Dale RG, Jones B. The incorporation of the concept of minimum RBE (RBEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int J Radiat Biol 2007;83:27-39.
4. Jones B, Carabe-Fernandez A, Dale RG. Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions. Br J Radiol 2005;79:254-7.
5. Dale RG, Jones B, Coles IP. The effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants. Br J Radiol 1994;67:639-45.
6. Brenner DL, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
7. Chappell R, Fowler JF, Ritter MA. In response to Drs Dale and Jones: "Is α/β for prostate tumours really low? In regard to Fowler et al IROBP 2001 50:1021-1031" [Letter]. Int J Radiat Oncol Biol Phys 2002;52:1427-8.
8. Dale RG, Hendry JH, Jones B et al. Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head & neck schedules. Clin Oncol 2002;14:382-393. (Update of [29]).
9. Jones B, Dale RG, Gaya A. Linear quadratic modelling of increased late normal tissue effects in special clinical situations. Int J Radiat Oncol Biol Phys 2006;64:948-953.
10. Jones B, Cominos M, Dale RG. Application of the Biological Effective Dose (BED) to estimate the duration of symptomatic relief and repopulation dose equivalent in palliative radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2003;55:736-742.
11. Jones B, Dale RG. Radiobiological compensation of treatment errors in radiotherapy. Br J Radiol 2008;81:323-326.
12. A12. Jones, B, Dale RG, Deehan C, Hopkins KI, Morgan DAL. The role of biologically effective dose (BED) in Clinical Oncology. Clin Oncol (UK RCR) 2001;13:71-81. (Pubitemid 32377501)
13. Jones B Dale RG. The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol 2005;78:939-944.
14. Jones B, Dale RG, Gaya A. Linear quadratic modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol 2005;79:254-257.
15. Plataniotis GA, Dale RG. Use of concept of chemotherapy-equivalent biologically effective dose to provide quantitative evaluation of contribution of chemotherapy to local tumor control in chemoradiotherapy cervical cancer trials. Int J Radiat Oncol Biol Phys 2008;72:1538-1543.
16. Fowler J. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (IJROBP 2007;68:1491-1495). Int J Radiat Oncol Biol Phys 2008;71:326-329.
17. Lee I, Eisbruch A. Mucositis versus tumor control: the therapeutic index of adding chemotherapy to irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 2009;75:1060-1063.
18. Hartley A, Sanghera P, Glaholm J et al. Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Clin Oncol 2009 Oncology (UK RCR) 2010;22:125-130.
19. Petereit DG, Sarkaria JN Chappell R, Fowler JF, Hartmann, Kinsella TJ, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301-7.
20. Leborgne F, Fowler JF, Leborgne JH, Zubizarreta E, Chappell. Fractionation in medium dose rate brachytherapy of cancer of the cervix. Int J Radiat Oncol Biol Phys 1996;35:907-14.
21. Leborgne F, Fowler JF, Leborgne JH, Zubizareta E, Curuchquin R. Medium-dose-rate brachytherapy of cancer of the cervix: preliminary results of a prospectively designed schedule based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1999;43:1061-4.
22. Leborgne, F, Fowler JF, Leborgne JH et al. Biologically Effective Doses in medium dose rate brachytherapy of cancer of the cervix. Radiat Oncol Invest 1997;5:289-99.
23. Fowler JF. Dose reduction factors when increasing dose in LDR or MDR brachytherapy of carcinoma of the cervix. Radiother Oncol 1997;45:49-54.
24. Clark BG, Souhami L. Roman TN, Chappell R, Evans MDC, Fowler JF. The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix using the linear quadratic model. Int J Radiat Oncol Biol Phys 1997;38:989-93.
25. Gasinska A, Fowler JF, Lind BK et al. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone. Acta Oncol 2004;43:657-66.
26. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy [Letter]. Int J Radiat Oncol Biol Phys 2000;46:516-17.
27. Mehta M, Scrimger R, Mackie R et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49:22-3.
28. Fowler JF, Tome W, Fenwick J, Meta M. Stereotactic body radiotherapy: a challenge to conventional radiation oncology. Int J Radiat Oncol Biol Phys 2004;60:1241-56.
29. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. RTOG 0236: Stereo-tactic body radiotherapy to treat medically inoperable early stage lung cancer patients. J Am Med Assoc 2010;303:11:1070-1076.
30. Bradley J, Bae K,Graham M, Byhardt R, Govindan R, Fowler J, et al. Primary analysis of phase II of a phase I/II dose intensification study using three dimensional conformal radiation therapy and concurrent chemotherapy for oatients with inoperable, non-smalll cell lung cancer. Radiation Oncology Group (RTOG 0117). J Clin Oncol 2010. Published ahead of print on April 5th, 2010 as10.1200/JCO.2009.27.1205.
31. Seppenwoolde Y, Lebesque J, de Jaeger K et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2003;55:724-35.
32. Chi A, Welsh J, Fowler J, Tome W, Meta M. Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiologic modeling and clinical outcome. Am J Clin Oncol; 2010 Accepted 19 Feb 2010.
33. 1-2 N0) non-small cell lung cancer. Radiother Oncol 1996;41:41-44.
34. Maguire J, Marks LB, Sibley GS, Herndon SE 2nd, Clough RW, Light KL et al. 73.6 Gy and beyond; hyperfractionated, accelerated radiotherapy for non-small cell lung cancer. J Clin Oncol 2001;19:705-11.
35. Cheung PCF, Yeung LTF, Basrur V, Ung YC, Balogh J, Danjoux CE. Accelerated hypofraction for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1014-1023.
36. Mehta MP, Wang W, Johnson D, Wagner H, Schiller J, Veeder M, et al. Induction chemotherapy followed by standard thoracic radiotherapy vs hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer: phase III study of the eastern cooperative oncology group (ECOG 2597). Int J Radiat Oncol Biol Phys 2003;57:S14.